
A world-first step toward repairing the Parkinson's brain
Lab-grown dopamine cells, transplanted into the brain, proved safe in the first human trial, and most patients cut their medication.
In Parkinson's disease, the brain slowly loses the nerve cells that make dopamine. The STEM-PD trial, led by Lund University with the University of Cambridge, Skåne University Hospital and UCL, has taken a landmark step: transplanting dopamine-producing cells, grown from stem cells, directly into the brains of eight patients.
A year on, seven have completed follow-up with no serious side effects linked to the transplanted cells, and six of them have substantially reduced their dopamine-replacement medication. PET brain imaging at six and twelve months showed the grafted cells surviving and taking hold. It is early, and larger trials lie ahead, but for the first time a therapy designed to replace what Parkinson's destroys has cleared its first human test.
“This represents an exciting new departure on repairing the brain of individuals with Parkinson's.”Professor Roger Barker, University of Cambridge



